FDA decision on relacorilant for ovarian cancer expected in July
The U.S. Food and Drug Administration (FDA) has agreed to review Corcept Therapeutics’ application seeking approval of relacorilant to treat platinum-resistant ovarian cancer. The…
News
Myeloma treatment combo sees 100% response rate in trial
Combination treatment with Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) led to a 100% response rate for 49 people with newly diagnosed…
Cancer network backs Syndax Revuforj for NPM1-mutated AML
The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 33 cancer centers, included Revuforj (revumenib) in its clinical practice guidelines for treatment of relapsed or…
New blood test detects multiple cancers at early stages
A new blood test capable of detecting multiple cancers at earlier, more treatable stages is now available in the U.S. for $689, its developer said.
Elahere approved in Canada for hard-to-treat ovarian cancer
The gynecological cancer therapy Elahere (mirvetuximab soravtansine) is now approved in Canada for adults with platinum-based, chemotherapy-resistant, ovarian, fallopian tube, or primary peritoneal cancer…
Survival time for myeloma patients nearly doubled since 2005
Over a 15-year period, the median survival time for people with myeloma has nearly doubled, increasing from 2.4 years for those diagnosed in 2005…
NASCAR car makeover driving awareness of pediatric blood cancer
The advocacy organization Blood Cancer United has teamed up with motor oil company Valvoline Global and auto racing group Hendrick Motorsports to raise awareness…
Rapid spread of rare pancreatic cancer to liver detailed in report
A rapidly growing pancreatic signet ring cell adenocarcinoma, a rare and aggressive type of pancreatic cancer, was reported to have spread to the liver…
Modeyso added to NCCN guidelines for rare brain cancer
The National Comprehensive Cancer Network (NCCN) has updated its clinical practice guidelines to include Modeyso (dordaviprone) as an appropriate option for a rare recurrent…
New drug for endometrial cancer wins FDA’s breakthrough status
The U.S. Food and Drug Administration (FDA) has awarded breakthrough therapy status to rinatabart sesutecan (Rina-S), an investigational treatment for certain cancers, including advanced endometrial…
